Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy

Knapp, F. F.; Kropp, J.; Liepe, Knut

doi:10.1007/174_2012_669

Cited by 6 publications

(3 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Table 2, detailed nuclear decay data are reported [7,9]. The peculiar characteristic of being produced by the decay of a parent nuclide allowed to develop the 188 W/ 188 Re generator system similarly to the technetium-99m, providing a long-term source for non-carrier added (nca) 188 Re to the Department of Nuclear Medicine [18,19]. Unfortunately, unlike the technetium-99m generator, the limited availability and high cost of GMP pharmaceuticals grade-generators have greatly limited the development of therapeutic agents based on 188 Re.…”

Section: Rhenium-188 Nuclear Properties and Productionmentioning

confidence: 99%

“…In particular, the SPECT/CT imaging study of the expression of HER2 will allow to increase the number of cases, while the result of the therapy will be the real goal. The obtained results will be compared with the existing gold standard HER2 expression detection by tissue immunohistochemical biopsy (IHC) and/or fluorescent in-situ hybridization (FISH) method and 18 F-FDG PET/CT imaging. Breast cancer patients who will be recruited for the study with 188 Re labeled anti-HER2 sdAb will have positive HER2; progression or relapse after standard treatment, including surgery, chemotherapy, radiotherapy, and targeted therapy; and will receive the radiopharmaceutical in a single dose of injection.…”

Section: "Rheniummentioning

confidence: 99%

See 1 more Smart Citation

Rhenium Radioisotopes for Medicine, a Focus on Production and Applications

et al. 2022

View full text Add to dashboard Cite

In recent decades, the use of alpha; pure beta; or beta/gamma emitters in oncology, endocrinology, and interventional cardiology rheumatology, has proved to be an important alternative to the most common therapeutic regimens. Among radionuclides used for therapy in nuclear medicine, two rhenium radioisotopes are of particular relevance: rhenium-186 and rhenium-188. The first is routinely produced in nuclear reactors by direct neutron activation of rhenium-186 via 185Re(n,γ)186Re nuclear reaction. Rhenium-188 is produced by the decay of the parent tungsten-188. Separation of rhenium-188 is mainly performed using a chromatographic 188W/188Re generator in which tungsten-188 is adsorbed on the alumina column, similar to the 99Mo/99mTc generator system, and the radionuclide eluted in saline solution. The application of rhenium-186 and rhenium-188 depends on their specific activity. Rhenium-186 is produced in low specific activity and is mainly used for labeling particles or diphosphonates for bone pain palliation. Whereas, rhenium-188 of high specific activity can be used for labeling peptides or bioactive molecules. One of the advantages of rhenium is its chemical similarity with technetium. So, diagnostic technetium analogs labeled with radiorhenium can be developed for therapeutic applications. Clinical trials promoting the use of 186/188Re-radiopharmaceuticals is, in particular, are discussed.

show abstract

Section: Rhenium-188 Nuclear Properties and Productionmentioning

confidence: 99%

Section: "Rheniummentioning

confidence: 99%

Rhenium Radioisotopes for Medicine, a Focus on Production and Applications

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Different radionuclides with suitable imaging and therapy properties such as holmium-166 ( 166 Ho) (T 1/2 = 26.8 h; E β − (max) = 1854 keV; E γ = 81 keV), rhenium-188 ( 188 Re) (T 1/2 = 16.9 h; E β − (max) = 2120 keV; E γ = 155 keV) and samarium-153 ( 153 Sm) have been explored to be used as a potential alternative to 90 Y [17][18][19][20][21]. However, 166 Ho and 188 Re have relatively short physical half-lives and the production of 166 Ho and the 188 Re generator requires high neutron flux nuclear reactors that are less available worldwide [22]. In comparison, 153 Sm has an optimum half-life of 46.3 h and it emits β − particles with medium energies of 808 (18%), 705 (50%) and 635 keV (32%), allowing maximum penetration in soft tissue up to 4.0 mm (average 0.8 mm) [17,23].…”

Section: Introductionmentioning

confidence: 99%

Development of neutron-activated samarium-153-loaded polystyrene microspheres as a potential theranostic agent for hepatic radioembolization

Tan

Wong

Kasbollah

et al. 2022

Nuclear Medicine Communications

View full text Add to dashboard Cite

Purpose Hepatic radioembolization is an effective minimally invasive treatment for primary and metastatic liver cancers. Yttrium-90 [90Y]-labelled resin or glass beads are typically used as the radioembolic agent for this treatment; however, these are not readily available in many countries. In this study, novel samarium-153 oxide-loaded polystyrene ([153Sm]Sm2O3-PS) microspheres were developed as a potential alternative to 90Y microspheres for hepatic radioembolization. Methods The [152Sm]Sm2O3-PS microspheres were synthesized using solid-in-oil-in-water solvent evaporation. The microspheres underwent neutron activation using a 1 MW open-pool research reactor to produce radioactive [153Sm]Sm2O3-PS microspheres via 152Sm(n,γ)153Sm reaction. Physicochemical characterization, gamma spectroscopy and in-vitro radionuclide retention efficiency were carried out to evaluate the properties and stability of the microspheres before and after neutron activation. Results The [153Sm]Sm2O3-PS microspheres achieved specific activity of 5.04 ± 0.52 GBq·g−1 after a 6 h neutron activation. Scanning electron microscopy and particle size analysis showed that the microspheres remained spherical with an average diameter of ~33 μm before and after neutron activation. No long half-life radionuclide and elemental impurities were found in the samples. The radionuclide retention efficiencies of the [153Sm]Sm2O3-PS microspheres at 550 h were 99.64 ± 0.07 and 98.76 ± 1.10% when tested in saline solution and human blood plasma, respectively. Conclusions A neutron-activated [153Sm]Sm2O3-PS microsphere formulation was successfully developed for potential application as a theranostic agent for liver radioembolization. The microspheres achieved suitable physical properties for radioembolization and demonstrated high radionuclide retention efficiency in saline solution and human blood plasma.

show abstract

Therapeutic Radionuclides: Production, Physical Characteristics, and Applications

Srivastava

Mausner

2013

Therapeutic Nuclear Medicine

View full text Add to dashboard Cite

Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy

Cited by 6 publications

References 187 publications

Rhenium Radioisotopes for Medicine, a Focus on Production and Applications

Rhenium Radioisotopes for Medicine, a Focus on Production and Applications

Development of neutron-activated samarium-153-loaded polystyrene microspheres as a potential theranostic agent for hepatic radioembolization

Therapeutic Radionuclides: Production, Physical Characteristics, and Applications

Contact Info

Product

Resources

About